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Introduction: Among gastrointestinal cancers, colorectal and gastric neoplasms
are the most frequent. The development of new targeted drugs improved the
efficacy of systemic therapy in advanced stages of those malignancies.
Areas covered: This review highlights the main biological processes impli-
cated in gastrointestinal cancer development and progression, such as
angiogenesis and epidermal growth factor receptor (EGFR) signaling path-
way. On these bases, anti-EGFR and anti-vascular endothelial growth factor
(VEGF) monoclonal antibodies in colorectal and gastric cancer are discussed.
Data about further monoclonal antibodies in development are also
reported.
Expert opinion: The use of monoclonal antibodies in colorectal and gastric
cancers showed the best outcomes when combined with chemotherapy, even
though single agent anti-EGFR antibodies seem active in particular setting of
metastatic colorectal cancer (CRC) patients. It is not well defined whether the
addition of anti-VEGF and anti-EGFR to chemotherapy could improve outcome
in those patients susceptible to CRC-related metastases resection. Little and
conflicting data are available about the role of these drugs in adjuvant setting.
Tests are available to select patients with higher probability to get benefit
from these treatments. Further biomarkers need to be evaluated to improve
this selection and achieve “tailorization” of systemic therapy.
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1. Introduction
Gastrointestinal cancers cover a great part of all malignancies in world population.
Some of them, such as colorectal cancer (CRC), are more frequent in Western
countries and represent some of the leading causes of cancer-related death. In the
last decades, the therapeutical approaches have been changed by the integration of
improved surgical procedures, radiation and systemic therapy. This improvement
was mainly influenced by the combination of different cytotoxic drugs and the
introduction of targeted drugs, in particular monoclonal antibodies (mAbs). Those
agents target the biological pathways, which are already known to drive the tumor
development and progression. To date, angiogenic process and epidermal growth
factor receptor (EGFR) pathway are recognized as the most relevant hallmarks of
gastrointestinal cancers. The addiction of cancer cell function to oncogenes impli-
cated in those pathways seems to be struck by specific mAbs, such as anti-EGFR,
anti-human epidermal growth receptor 2 (HER2) and anti-vascular endothelial
growth factor (VEGF).
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2. Biological pathways in gastrointestinal
carcinogenesis
2.1 Angiogenic pathway
Among the hallmarks of cancer, angiogenesis has a predomi-
nant role in gastrointestinal cancers. This is a process of the
formation of new blood vessel within the tumor, essentially
to provide nutrients and oxygen. VEGF is an endothelial
cell-specific mitogen and an angiogenesis-inducer released by
a variety of tumor cells and expressed in human tumors
in situ [1]. VEGF was first isolated in 1983 as a factor leading
to increased vascular permeability in tumors and was thus also
called vascular permeability factor [2]. VEGF (also designated
as VEGF-A) is the founding member of a family of homodi-
meric glycoproteins that are structurally related to the
platelet-derived growth factors; this family also includes pla-
centa growth factor, VEGF-B, VEGF-C, VEGF-D and
VEGF-E. This VEGF family of proteins selectively binds
with different affinities to at least five distinct receptors:
VEGF-A binds to receptors, VEGFR-1 and VEGFR-2.
Recently, the neuropilins have been identified as co-
receptors for specific VEGF isoforms [3]. Targeted inactivation
of VEGFR-1 and VEGFR-2 as well as neuropilin-1 in mice
resulted in defects in the formation of blood vessel and em-
bryonic lethality, demonstrating further the importance of
VEGF-A for appropriate vascular development [4-6]. A variety
of physiological and pathological processes are associated with
upregulation of components of the VEGF/VEGFR-system,
including embryogenesis, the female reproductive cycle, preg-
nancy, wound healing, tumor growth, diabetic retinopathy
and ischemic diseases [7]. In the search for mechanisms and fac-
tors that are able to influence the VEGF expression during
these processes, many cytokines and growth factors have been
shown to modulate VEGF gene expression [8]. For example,
TNF-a and bFGF are able to induce VEGF gene expression
in vitro; also, glucose deficiency has been shown to increase
VEGF expression [9]. The most important and intensively
studied inducer of VEGF gene expression, however, is
hypoxia [10-14]. Under hypoxic conditions, VEGF expression is
mediated through the activation of specific hypoxia-inducible
transcription factors, HIF-1 and HIF-2. In addition, VEGF
upregulation during hypoxia is also achieved by an increase in
the stability of its mRNA51 and by the efficient hypoxic trans-
lation of the VEGF mRNA which is mediated by an internal
ribosomal entry site [15-18]. In endothelial cells, VEGFR-2 is
considered to be the major signaling receptor, while VEGFR-1
acts as a sink to trap an excess of VEGF. Endothelial prolifera-
tion is mediated via the Ras-Raf-MAP (mitogen-activated pro-
tein)-kinase pathway, while protein kinase C activation is
involved in endothelial migration and vascular permeability.
The role of VEGF as a survival factor for endothelial cells is
mediated by the phosphoinositol-3 (PI3) kinase-AKT signaling
pathway [19].
2.2 EGFR/HER2 pathway
The ErbB family of receptors (also known as type I receptor
tyrosine kinases [TKs]) includes four homologous receptors:
the EGFR (ErbB1/EGFR/HER1); ErbB2 (HER2/neu);
ErbB3 (HER3) and ErbB4 (HER4) [20]. The EGFR is a
membrane-bound TK that contributes to signaling cascades
with multiple procarcinogenic effects, including cell prolifera-
tion, motility, adhesion, invasion, cell survival and angiogen-
esis. EGFR overexpression has been detected in several human
cancers, including CRC, and correlates with progression and
metastasis. HER2 overexpression or gene amplification has
been observed in multiple cancer types, including gastric
tumors. As with EGFR, HER2 overexpression has been
observed in aberrant crypt foci in human colon [21,22]. These
receptors are composed of an extracellular binding domain,
a transmembrane lipophilic segment, and an intracellular pro-
tein TK domain with a regulatory COOH-terminal segment.
There is a rich crosstalk among the ErbB family that regulates
the cellular effects mediated by these receptors. At least six dif-
ferent ligands, known as EGF-like ligands, bind to the EGFR.
These ligands include EGF, transforming growth factor a,
amphiregulin, heparin-binding EGF, betacellulin and epire-
gulin. A second class of ligands, collectively termed heregu-
lins, binds directly to HER3 and/or HER4. After ligand
binding, the ErbB receptors become activated by dimerization
between two identical receptors (homodimerization) or
between different receptors of the same family (heterodimeri-
zation). After receptor dimerization, activation of the intrinsic
protein kinase activity and tyrosine autophosphorylation
occur, recruiting and phosphorylating several intracellular
substrates involving the Ras-Raf-MAPK, the PI3k-Akt and
other signaling pathways that regulate multiple biological
processes, including apoptosis and cellular proliferation. RAS
protein function is normally regulated by cycling between inac-
tive GDP bound and active GTP-bound forms. Signaling is
terminated when RAS-GTP is hydrolyzed to the RAS--GDP
inactive complex by GTPase-activating proteins. Activated
RAS recruits Raf protein to the cell membrane and phosphor-
ylates it, triggering serine-threonine kinase activity of various
Article highlights.
. The mAbs in gastrointestinal cancer are directed against
VEGF-related and EGFR/HER2-related pathways.
. Gastrointestinal cancers, like other tumors, develop
‘oncogene addiction’, which could be inhibited by
specific mAbs.
. Bevacizumab is an anti-VEGF mAb used in mCRC
treatment in combination with chemotherapy.
. Cetuximab and panitumumab are anti-EGFR mAbs
delivered alone or in combination with chemotherapy.
. Trastuzumab is an anti-HER2 mAb, which was recently
approved for advanced GC overexpressing HER2.
. New mAbs are under development for
gastrointestinal cancers.
This box summarizes key points contained in the article.
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proteins. Finally active mitogen-activated protein kinases
(MAPKs) can translocate to the nucleus, where they regulate
the activity of several transcription factors for the expression
of multiple genes of survival and proliferation [22].
3. Approved mAbs for gastrointestinal
cancers
3.1 Bevacizumab
The introduction of molecules, such as oxaliplatin and irino-
tecan, in the treatment of metastatic CRC (mCRC) achieved
improved response rate and overall survival (OS). Recently
the addition of targeted drugs to standard chemotherapy regi-
mens has improved these results. Bevacizumab is a humanized
mAb that inhibits VEGF as key modulator of angiogenesis. It
was initially tested in a Phase II study, comparing the combi-
nation of 5-fluorouracil/Leucovorin (5FU/LV) and bevacizu-
mab with 5FU/LV alone [23]. Subsequently, a Phase III trial
evaluated patients with previously untreated mCRC who
were randomly assigned to receive irinotecan, bolus fluoroura-
cil and leucovorin (Saltz’ IFL regimen) plus bevacizumab
or IFL plus placebo. The median duration of survival was
20.3 months in the group treated with IFL plus bevacizumab
as against 15.6 months in the group treated with IFL plus pla-
cebo. These results were very significant if considered that the
control arm was a standard first-line chemotherapy regi-
men [24]. Other recent trials have also failed to demonstrate
the same statistically significant results in survival, particularly
with other backbone regimens, such as isolated capecitabine
or oxaliplatin-containing regimens, such as FOLFOX or
XELOXs plus placebo or bevacizumab in first-line mCRC
(mOS 19.9 vs 21.3 months in bevacizumab group) [25]. Sub-
sequently, a three-arm multicenter randomized study
(E3200 trial) assigned 829 mCRC patients previously treated
with a fluoropyrimidine and irinotecan to one of three treat-
ment groups: oxaliplatin, fluorouracil, and leucovorin (FOL-
FOX4) with bevacizumab; FOLFOX4 without bevacizumab
or bevacizumab alone. It showed that the combination of che-
motherapy plus bevacizumab was better than chemotherapy
alone (median progression-free survival [mPFS] was 7.2 vs
4.8 months) but even that bevacizumab alone does not have
the same effect as combination regimen (mPFS 2.7 vs
7.2 months). These observations suggested that VEGF path-
way is a probable mainstream. This phenomenon could be
explained by the effect of bevacizumab to improve tumor vas-
cular architecture and let chemotherapy have a higher cytotox-
icity on cancer cells, as shown in some preclinical studies [26].
Moreover, as demonstrated in the first BEAT trial, bevacizu-
mab plus conventional first-line chemotherapy regimens had
an important role before surgery to improve R0 liver metasta-
ses resections rate safely in patients originally deemed unre-
sectable giving a rationale to make prospective randomized
trials evaluating the use of bevacizumab before resection of
liver metastases [27]. Another point of discussion is the proba-
ble role of bevacizumab to prevent recurrence after liver
metastasectomy. We know that most patients will develop
local or distant recurrences after surgery for colorectal liver
metastases, that adjuvant chemotherapy with 5FU-based
chemotherapy has shown to improve the prognosis of these
patients and that bevacizumab prolongs PFS and improves
the response rate of chemotherapy in metastatic setting. For
these reasons, recent controversial studies have explored a
hypothetical role of anti-VEGF by adding the angiogenesis
inhibitor to an adjuvant standard regimen chemotherapy to
improve disease-free survival (DFS) for patients after resection
of colorectal liver metastases. Different results were found: the
HEPATICA Phase III trial demonstrated a favorable not-
statistically significant trend in 2-year DFS (52 vs 70%) by
adding bevacizumab to CAPOX chemotherapy after resection
of colorectal liver metastases (p = 0.074). This study does not
clarify the role of bevacizumab in combination with chemo-
therapy as adjuvant treatment for those mCRC patients resected
for liver metastases [28]. A trial presented during ASCO
2011 annual meeting in which patients after complete resection
of liver-confined metastases from CRC were treated with cyto-
toxic regimens (fluoropyrimidines alone or irinotecan or oxalipla-
tin-based) with or without bevacizumab. After metastasectomy,
the median follow-up time was 21 months, the median OS
and DFS were 54 and 13 months, respectively, meaning that
adding bevacizumab to cytotoxic regimens has no impact on
clinical outcomes with respect to DFS and OS after complete
resection of liver-confined metastases for CRC [29].
3.2 Cetuximab
About use of cetuximab in gastrointestinal tumors, in 2004,
the FDA has tried to use the cetuximab on the basis of the
EPIC trial data, a multicenter open-label Phase III study,
which showed an advantage in terms of time-to-progression
and response rate when cetuximab was associated with irinote-
can compared to irinotecan alone. OS was similar between
study groups, possibly influenced by the large number of
patients in the irinotecan arm who received cetuximab and iri-
notecan at progression [30]. Moreover, in the BOND trial, a
randomized, open-label Phase II study, authors were able to
demonstrate the effectiveness of cetuximab either in mono-
therapy or in combination with irinotecan in patients with
irinotecan-refractory CRC. Although both schedules show
activity in this subset of patients, combination therapy had a
significantly higher response rate (22.9 vs 10.8%) and longer
time to progression (4.1 vs 1.5 months), suggesting that the
combination of irinotecan and cetuximab should be preferred
for patients with irinotecan-refractory cancer [31]. Other two
important trials, CRYSTAL and OPUS, investigated the use
of cetuximab associated with chemotherapy regimens as
first-line treatment for mCRC. About CRYSTAL, a random-
ized, open-label, multicenter trial, authors verified the efficacy
of cetuximab plus irinotecan, fluorouracil and leucovorin
(FOLFIRI) versus FOLFIRI alone as first-line treatment for
mCRC and sought associations between the mutation status
of the KRAS gene in tumors and clinical response to
Monoclonal antibodies in gastrointestinal cancers
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cetuximab. The primary endpoint was PFS. Although benefit in
terms of OS between the two treatment groups (hazard ratio
[HR] = 0.93, p = 0.31) is not shown in this study, the data also
showed that the treatment FOLFIRI + cetuximab when com-
pared with FOLFIRI alone reduces the risk of disease progression
(HR = 0.85, p = 0.048) and that benefit of cetuximab was limited
to patients with KRAS wild-type tumors (HR = 0.68) [32].
Subsequent retrospective subgroup analysis of the study
data revealed an advantage in terms of OS (23.5 v
20 months, HR = 0796, p = 0.0093) in the subgroup of
patients KRAS wild type. Of these, in particular, the BRAF
wild type had a significantly reduced risk of disease progres-
sion (HR = 0637, p = 0.0013) and significantly increased
odds of response (odds ratio = 2.175, p < 0.001) compared
with those who received FOLFIRI alone demonstrating
how BRAF V600E mutation probably indicated poor
prognosis in patients with KRAS wild-type disease in both
treatment groups [33].
In the OPUS trial, a multicenter, not controlled, open-
label, Phase II study, authors investigated the efficacy of
cetuximab in combination with oxaliplatin-based standard
chemotherapy (FOLFOX-4), compared to chemotherapy
alone, in previously untreated mCRC patients. The primary
endpoint was response rate. In cetuximab arm a better
response rate was achieved (46 vs 36%). Median PFS and
median duration of response were 12.3 and 10.8 months,
respectively. The results from the OPUS trial prompted the
European approval for the extension of the use of cetuximab
to first-line treatment in mCRC patients expressing EGFR
and KRAS wild-type [34].
But these interesting results are conflicting with other
results from COIN trial, a randomized controlled trial, in
which patients who had not received previous chemotherapy
for advanced CRC were randomly assigned to oxaliplatin
and fluoropyrimidine chemotherapy (arm A), the same com-
bination plus cetuximab (arm B) or intermittent chemother-
apy (arm C). The comparison of arm A and arm B, for
which the primary outcome was OS in patients with KRAS
wild-type tumors, confirmed that OS did not differ between
treatment groups and control group (17.0 vs 17.9 months).
Similarly, there was no effect on PFS. Overall response rate
increased from 57% with chemotherapy alone to 64% with
addition of cetuximab. However, toxicity rates were higher:
grade 3 -- 4 skin and gastrointestinal side effects were
increased with cetuximab (14 vs 114 and 67 vs 97 patients
in the control group vs the cetuximab group with KRAS
wild-type tumors, respectively). This trial did not confirm a
benefit of addition of cetuximab to oxaliplatin-based chemo-
therapy in first-line treatment of patients with advanced
CRC and for this reason the use of cetuximab in combination
with oxaliplatin and capecitabine in first-line chemotherapy in
patients with widespread metastases was not recommended
by authors [35].
Results are also interesting from CELIM trial in which
patients underwent resection with curative intent of previously
unresectable metastases. The aim of this study was to explore
if the addition of cetuximab to neoadjuvant chemotherapy in
patients with CRC with unresectable liver metastases can lead
to a decrease in tumor size and a subsequent higher probabi-
lity for curative (R0) resection. The study involved those
patients who had undergone resection of the primary tumor,
but who later developed liver metastases deemed unresect-
able. Enrolled patients were divided into two groups, one
treated with cetuximab plus oxaliplatin, fluorouracil and
folinic acid (FOLFOX6; group A) and the other with cetux-
imab plus irinotecan, fluorouracil and folinic acid (FOLFIRI;
group B). In 68% of patients in group A and in 57% of those
in group B a complete or partial response was achieved. The
response was higher (70%) in patients whose tumors had
KRAS wild-type (70%) than those with mutated KRAS
(41%), remarking the predictive role of this mutation for
resistance to cetuximab. Curative surgery was possible in
34% of patients. Results have shown that the addition of
cetuximab achieved a higher tumor response rate and also a
higher rate of radically resectable liver metastases [36].
3.3 Panitumumab
On 2006, US Food and Drug Administration granted
approval to panitumumab for the treatment of patients
with EGFR-expressing, mCRC with disease progression on
or following fluoropyrimidine-, oxaliplatin-, and irinotecan-
containing chemotherapy regimens. The efficacy as single agent
was studied in randomized controlled trial (463 patients). In
this study, patients were randomized to receive best supportive
care (BSC) with or without panitumumab, administered until
disease progression or intolerable toxicity. At progression,
patients in the BSC-alone arm were eligible to receive panitu-
mumab. The primary endpoint was PFS. Although median
PFS was similar in both treatment arms (~ 8 weeks), the
mean PFS was ~ 50% longer among patients receiving panitu-
mumab than among those receiving BSC alone (96 vs 60 days,
respectively) [37]. After this approval, many studies tested pan-
itumumab in combination with chemotherapy. When admin-
istered as first- or second-line treatment in combination with
chemotherapy with FOLFOX as first-line treatment, the
PRIME trial, panitumumab plus chemotherapy prolonged
PFS to a significantly greater extent than chemotherapy alone
(9.6 vs 8 months) in patients with wild-type KRAS tumors;
no significant difference between groups in OS was seen.
This lack of impact on OS suggests that panitumumab is not
as powerful as cetuximab, a perception that probably continues
to be taken into account among clinicians and which probably
has limited the acceptance of panitumumab in clinical
practice [38]. In patients with mutant KRAS tumors, PFS was
significantly shorter with panitumumab plus oxaliplatin-
based chemotherapy than with oxaliplatin-based chemother-
apy alone in the first-line treatment trial, with no significant
difference between patients receiving panitumumab plus
irinotecan-based chemotherapy (FOLFIRI) and those receiving
FOLFIRI alone in the second-line treatment trial [39]. The
G. Bronte et al.
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possibility that panitumumab was effective in patients with
KRAS Wild-Type Colorectal Cancer after Progression on
Cetuximab (PANERB trial -- Matges et al.) was also explored.
Authors concluded, however, that as long as markers predictive
of response to treatment with panitumumab were not generated,
this option should not be adopted as effective because of its
limited efficacy only in a small subset of patients [40].
3.4 Trastuzumab
Chemotherapy improved survival compared to BSC in
patients with advanced gastric cancer (GC) and combination
chemotherapy was superior to monotherapy [41]. About 20%
of gastric and esophagogastric junction tumors overexpress
HER2, providing a rationale in the past 20 years to investigate
a biological target therapy as trastuzumab, a mAb directed
against HER2, in this neoplasm [42]. The efficacy of trastuzu-
mab was demonstrated through the ToGA trial, an open-
label, international, Phase III, randomized controlled trial,
that investigated trastuzumab in combination with chemo-
therapy for first-line treatment of HER2-positive advanced
gastric or gastroesophageal junction cancer. Median OS was
favorable for trastuzumab plus chemotherapy arm (13.8 vs
11.1 months), that corresponded to a 26% reduction in the
death rate. The results showed that this combination could
represent a new standard therapy for patients affected by
inoperable/metastatic gastric or gastroesophageal junction
cancer and this use of modern biological targeted therapies
as trastuzumab will represents a new way of conceiving the
chemotherapy of GC (Table 1) [43].
4. Molecular tests for patient selection
4.1 KRAS and BRAF mutational status in CRC
KRAS proto-oncogene is a key component of the system of
signal transduction downstream of EGFR and it plays a critical
role in the regulation of cell growth and proliferation. The
presence of activating mutations in KRAS stimulates the
RAS/MAPK signaling pathway independent of EGFR giving
the advantage to the cell to avoid apoptosis and to grow and
proliferate. It has been demonstrated that 40 -- 45% of all colo-
rectal adenocarcinomas are carriers of those mutations of KRAS
and the most of them are located on codon 12 (70%) and
codon 13 (30%) and less in codon [44]. Several studies showed
that the activity in mCRC of anti-EGFR mAbs (cetuximab and
panitumumab) is strongly linked to the wild type mutational
status of Kirsten-Ras gene. For this reason KRAS-testing has
become mandatory to choose the most appropriate therapy
for these patients [45]. Moreover, the treatment with anti-
EGFR mAbs in combination with FOLFOX-based chemother-
apy in mCRC patients, carriers of mutations in the KRAS gene,
has been shown to be even detrimental [46]. Some studies report
that colorectal adenocarcinomas with KRAS WT gene showed a
better prognosis then KRAS mutated ones. Today the relation
between prognosis and KRAS mutational status remains contro-
versial, and further studies are needed to establish the real clinical
role of this biomolecular marker in mCRC. Mutational status of
KRAS can be assessed with several laboratory techniques but the
most commonly used are direct sequencing and real-time
PCR. Direct sequencing is the most diffuse method and is
Table 1. Main studies regarding the combination of approved mAbs in gastrointestinal cancers and chemotherapy.
Study Treatment Patients
(n)
Line of
treatment
RR (%) Median PFS
(months)
Median
OS
AVF2192 g 5FU/LV vs 5FU/LV + BEVACIZUMAB 209 Second 15.2
26
5.5
9.2
12.9
16.6
AVF2107 g IFL vs IFL + BEVACIZUMAB 813 First 34.8
44.8
6.2
10.6
15.6
20.3
NO16966 FOLFOX-4 or CAPOX vs FOLFOX-4 or
CAPOX + BEVACIZUMAB
1,400 First 49.2
46.5
8
9.4
19.9
21.2
E3200 FOLFOX vs FOLFOX + BEVACIZUMAB 585 Second 8.6
22.2
4.5
7.5
10.8
13
CRYSTAL FOLFIRI vs FOLFIRI + CETUXIMAB
(KRAS WT)
666 First 40
57
8.4
9.9
20
23.5
OPUS FOLFOX vs FOLFOX + CETUXIMAB
(KRAS WT)
179 First 34
57
7.3
8.3
19.5
22.8
COIN XELOX/FOLFOX vs XELOX/FOLFOX + CETUXIMAB
(KRAS WT)
729 FIRST 50
59
8.6
8.6
17.9
17
EPIC IRINOTECAN vs IRINOTECAN + CETUXIMAB 1,298 SECOND 4.2
16.4
2.6
4
9.9
10.7
PRIME FOLFOX vs FOLFOX + PANITUMUMAB
(KRAS WT)
656 FIRST 48
57
8.6
10
19.7
23.9
20100007 BSC vs BSC + PANITUMUMAB
(KRAS WT)
329 THIRD 0
17
8 weeks
16 weeks
ND
ND
TOGA CISPLATIN -- 5FU or CAPECITABINE vs
CISPLATIN -- 5FU or CAPECITABINE + TRASTUZUMAB
584 FIRST 34.5
47.3
5.5
6.7
11.1
13.8
RR: Response rate.
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able to detect all mutations in exons 2 and 3 of KRAS gene
despite low sensitivity. On the other hand, real-time PCR
uses primers, having sufficient level of sensitivity, that bind
the most common mutations in codon 12 and 13. The detec-
tion limit of these two techniques is around 20% of the muta-
tion rate. Pyrosequencing is a technology which operates by
synthesis. It represents another important method to detect
KRAS mutations. It allows a real-time monitoring of DNA
synthesis by the detection of the bioluminescence produced
at the end of a cascade of enzymatic reactions triggered by
the incorporation of a nucleotide. This technique has some
advantages in comparison with standard sequencing techniques
including a higher sensitivity and the possibility of sequencing
shorter fragments of DNA, thus solving problems related to
DNA over-fragmentation. The p.G13D mutation represents
another target of KRAS gene, whose prognostic significance
must still be well determined, in comparison with other
KRAS mutations. It seems that the use of cetuximab in addi-
tion to first-line chemotherapy gives benefits to patients with
KRAS G13D-mutant tumors. These data have been confirmed
by a recent analysis by Tejpar et al. in which the associations
between tumor KRAS mutation status (wild-type, G13D,
G12V or other mutations) and PFS, survival, and response
were investigated in pooled data from 1,378 evaluable patients
from the CRYSTAL and OPUS studies (Tables 2 and 3). Of
533 patients with KRAS-mutant tumors, 83 (16%) had
G13D, and these patients, treated with cetuximab in addition
to chemotherapy showed an improved PFS (median = 7.4 vs
6 months; HR = 0.47, p = 0.039) and tumor response
(40.5 vs 22%; odds ratio = 3.38, p = 0.042) but not survival
(median = 15.4 vs 14.7 months; HR = 0.89, p = 0.68), in
comparison with chemotherapy alone [9]. BRAF mutation
represents another genetic target to evaluate for establishing
tumor’s response to anti EGFR mAbs. BRAF gene codificates
for a kinase that regulates part of MAP kinase/ERKs signaling
pathway and it is involved in many cells functions such as
mitosis, differentiation and secretion. Mutations in B-raf
have been described as an alternative oncogenic event in
patients affected with mCRC without KRAS mutations. The
most common of them is a DNA missense which leads to a
valine to glutamic acid substitution (V600E). These mutations
have been found ~ 10% of CRCs and it is mutually exclusive
with KRAS mutations. A retrospective analysis conducted by
Di Nicolantonio et al., showed that a BRAF wild-type status
is required for response to panitumumab or cetuximab and
could be used to select patients who are eligible for the treat-
ment. They analyzed responses, KRAS and BRAF status,
time to tumor progression and OS of cohort of 113 mCRCs
treated with cetuximab or panitumumab. In 30% of the
patients, KRAS mutations were present and showed resistance
to cetuximab or panitumumab. None of the V600E BRAF
mutated/KRAS WT patients (11 of 79 KRAS WT patients)
responded to the treatment and had significantly shorter PFS
(p = 0.011) and OS (p < 0.0001) than wild-type patients [47].
4.2 HER2 expression in GC
The detection of HER2 overexpression, or HER2 gene ampli-
fication, represents the most important goal of the biological
characterization of gastric and gastroesophageal junction can-
cers. The ToGA trial, a randomized, open, international,
multicentric Phase III trial, showed a significant benefit with
the introduction of trastuzumab administered in combination
with chemotherapy, for the treatment of HER2-positive met-
astatic gastric and gastroesophageal junction cancer, with a
Table 2. Correlation between KRAS mutation status and efficacy endpoints of cetuximab-based treatment from
CRYSTAL trial.
EMR 62
202-013
(CRYSTAL) [32]
KRAS wild type KRAS MUT
FOLFIRI + cetuximab
(n = 316)
FOLFIRI
(n = 350)
FOLFIRI + cetuximab
(n = 214)
FOLFIRI
(n = 183)
Time of OS
Median OS (months) 23.5 20 16.2 16.7
HR 0.796 1.035
(95% CI) [0.670 -- 0.946] [0.834 -- 1.284]
p value 0.0094 0.7551
Time of PFS
Median PFS (months) 9.9 8.4 7.4 7.7
HR 0.696 1.171
(95% CI) [0.558 -- 0.867] [0.887 -- 1.544]
p value 0.0012 0.2661
Tumor response
ORR (%) 57.3 39.7 31.3 36.1
Odds ratio 2.0693 0.8220
(95% CI) [1.5154 -- 2.8258] [0.5441 -- 1.2419]
p value < 0.001 0.3475
CI: Confidence interval; FOLFIRI: Irinotecan plus infusional 5-FU/FA; ORR: Objective response rate (patients with complete response or partial response); OS: Overall
survival; PFS: Progression-free survival.
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26% reduction of the risk of death (HR = 0.74) and a median
OS of 3 months [43]. The correct determination of HER2
expression by immunohistochemistry (IHC) is in fact indi-
cated in patients affected by gastric and gastroesophageal
junction cancers in the metastatic and locally advanced set-
tings, and it is very important to establish a valid therapeutic
strategy for the treatment of these malignancies. A modified
scoring system has been developed to identify HER2+
patients to treat with trastuzumab. IHC examination defines
membrane status of HER2 with three levels of expression:
0+ (negative) with no reactivity or membranous reactivity
in < 10% of tumor cells, 1+ (negative) with a faint/barely
perceptible membranous reactivity in ‡ 10% tumor cells (or
cells are reactive only in part of the membrane), 2+ (equivo-
cal) with a weak-to-moderate complete basolateral or lateral
membranous reactivity in ‡ 10% tumor cells, 3+ (positive)
with a strong complete basolateral or lateral membranous
reactivity in ‡ 10% tumor cells, according to the HER2 scor-
ing system for GC (Table 4). A HER2 0 -- 1+ score excludes
the patient from the treatment with trastuzumab, whereas a
3+ score establish the membrane overexpression of HER2
receptor and leads to the possibility of using trastuzumab in
combination with chemotherapy. An equivocal data is repre-
sented by a 2+ score which requires a second-level test with
in situ hybridization techniques (FISH or CISH) to assess
the state of amplification of HER2 gene. There are some dif-
ferences between breast and gastric/junction cancer in HER2
testing: more tumor heterogeneity in GC than in breast can-
cer cells (4.8 vs 1.4%); incomplete membrane immunore-
activity due to higher frequency of glandular formations in
gastric tissue; a higher frequency of FISH+/IHC 0 -- 1 in
GC cells than in breast cancer [48].
5. Monoclonal antibodies in development
for clinical use
Despite advances in clinical diagnostics, surgical techniques,
chemotherapy and immunotherapy regimes, the prognosis of
gastrointestinal cancers in the metastatic phase remains critical
and new studies are needed to identify new molecules in order
to offer new opportunities to patients. In this section we will
look at the preclinical and clinical studies on new mAbs.
5.1 Edrecolomab
Edrecolomab is a murine mAb directed against the transmem-
brane glycoprotein epithelial cell adhesion molecule (EpCAM).
This antigen is normally expressed on many human epithelia
and overexpressed in many malignancies, including CRC.
Preclinical data showed that it works by antibody-dependent
cell-mediated cytotoxicity [49]. Early clinical data indicate an anti-
tumor activity and could be beneficial for advanced cancer
patients. A small Phase III trial in patients with resected stage III
CRC using edrecolomab was designed, before its efficacy was
formally demonstrated in cancer patients at advanced stage [50].
Edrecolomab achieved a significant improvement of
relapse-free and OS, similar to that observed for FU plus leu-
covorin. These results yielded the approval of edrecolomab for
adjuvant therapy in colon cancer in Germany [51]. Four large
prospective randomized trials were prompted in patients
with stage II and stage III colon cancer to confirm the results
of this pivotal trial.
Two of these trials compared edrecolomab alone with no
treatment in stage II disease and the others edrecolomab alone
versus chemotherapy with 5-FU plus leucovorin or the com-
bination of chemotherapy and edrecolomab in stage III colon
Table 3. Correlation between KRAS mutation status and efficacy endpoints of cetuximab-based treatment from
OPUS trial.
EMR 62
202-047
(OPUS) [34]
KRAS wild type KRAS MUT
FOLFOX4 + cetuximab
(n = 82)
FOLFOX4
(n = 97)
FOLFOX4 + cetuximab
(n = 77)
FOLFOX4
(n = 59)
Time of OS
Median OS (months) 22.8 18.5 13.4 17.5
HR 0.855 1.290
(95% CI) [0.599 -- 1.219] [0.873 -- 1.906]
p value 0.3854 0.2004
Time of PFS
Median PFS (months) 8.3 7.2 5.5 8.6
HR 0.567 1.720
(95% CI) [0.375 -- 0.856] [1.104 -- 2.679]
p value 0.0064 0.0153
Tumor response
ORR (%) 57.3 34 33.8 52.5
Odds Ratio 2.5512 0.4591
(95% CI) [1.3799 -- 4.7169] [0.2280 -- 0.9244]
p value 0.0027 0.0290
CI: Confidence interval; FOLFOX4: Oxaliplatin plus infusional 5-FU/FA; ORR: Objective response rate (patients with complete response or partial response); OS:
Overall survival; PFS: Progression-free survival.
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cancer. These studies showed a lack of efficacy of edrecolomab
in the adjuvant setting of colon cancer patients [52,53].
5.2 Catumaxomab
Catumaxomab is a hybrid, trifunctional and bispecific mAb.
It combines two half antibodies of mouse anti-EpCAM
IgG2a and rat anti-CD3 IgG2b. Catumaxomab is defined as
bispecific because it can bind two different antigens and tri-
functional because it is active through three different events.
Preclinical studies have, in fact, shown that one antigen bind-
ing site recognizes the EpCAM on tumor cells, the other
antigen binding site binds to CD3, a component of the
T-cell receptor complex, and the Fc-fragment binds to FcgR
Types I and III-positive cells, including macrophages,
dendritic cells and natural killer cells [54-56].
Catumaxomab has been studied for the intraperitoneal
treatment of malignant ascites in patients with EpCAM-
positive epithelial tumors, when standard therapy is not avail-
able or no longer feasible. Treatment consists of four constant-
rate intraperitoneal infusions via intraperitoneal catheter at
doses of 10, 20, 50 and 150 µg of catumaxomab on days 0,
3, 7 and 10 as proposed by the result of a Phase I/II trial.
This treatment was compared with paracentesis alone in a
pivotal Phase II/III study [57-58].
Catumaxomab can prolong puncture-free survival in
patients with malignant ascites requiring symptomatic thera-
peutic paracentesis. Side effects are explained by the cytokine
release induced by the drug and are usually reversible. These
commonly include fever, chills, nausea and vomiting.
5.3 Anti-VEGFR mAbs
Ramucirumab (IMC-1121B) (Ram) is a fully human mAb
which binds the extracellular domain of VEGFR-2 with a
high affinity. It binds the ligand-binding domain of VEGFR-2,
thus blocking the interaction with VEGF [59]. In a Phase I trial,
Ram has been administered weekly and the most important side
effects were hypertension, thrombosis, proteinuria and bleed-
ing. The maximum weekly tolerated dose was 13 mg/kg [60].
Another Phase I study evaluated the q2-3W administration,
with a similar profile of toxicity [61]. Many studies (Phases II
and III) are now testing Ram for various solid tumors and
most of them focus on gastrointestinal cancers, both as single
agent and in combination with chemotherapy. A Phase III trial
(NCT00917384 -- REGARD) investigated Ram plus BSC in
comparison with placebo plus BSC in patients affected by
metastatic GC following disease progression after first-line
platinum- or fluoropyrimidine- containing combination ther-
apy. Final results of this study have been presented as a late-
breaking poster abstract at ASCO GI 2013 Congress. The
addition of Ram obtained an improvement of 0.8 months in
OS (median OS: 5.2 vs 3.8 months; HR = 0.776,
p = 0.0473) and 0.8 months in PFS (median PFS = 2.1 vs
1.3 months; HR = 0.483, p < 0.0001) [62]. Another Phase III
study (NCT01170663 -- RAIMBOW) is evaluating the use
of Ram in association with paclitaxel versus paclitaxel alone
as second-line treatment of metastatic gastric adenocarcinoma.
A Japanese Phase Ib study (NCT01286818) is also studying the
association of FOLFIRI regimen plus Ram in patients with
mCRC. Partial or final results of these and other studies are
expected to be available in the months to come and it is hoped
that they will meet the high expectations regarding the efficacy
of this new drug.
Icrucumab (IMC-18F1) is a fully human IgG1 mAb devel-
oped against human VEGFR-1/FLT-1 with antiangiogenetic
and antineoplastic activities. It binds VEGFR-1 with high
affinity and blocks its activity preventing the second mess-
engers cascade and so inhibiting tumor neoangiogenesis.
A Phase I study by Krishnamurthi et al. has been published
as abstract for the 2008 ASCO meeting. In this trial designed
to evaluate the safety, pharmacokinetics, pharmacodynamics
and immunogenicity of IMC-18F1, 14 patients were treated
with the drug and received it at the weekly dose of 2, 3, 6,
12 mg/kg, 15 mg/kg every 2 weeks, and 20 mg/kg every
3 weeks. At the date of submission no grade > 2 adverse events
or dose-limiting toxicities has been observed [63]. A Phase II
randomized trial (NCT01111604), which is still recruiting
Table 4. HER2 assessment by IHC.
HER2 score Surgical specimen pattern Biopsy specimen pattern HER2 overexpression
assessment
0 With no reactivity or membranous
reactivity in < 10% of tumor cells
No reactivity or no membranous
reactivity in any tumor cell
Negative
1+ Faint/barely perceptible membranous
reactivity in ‡ 10% tumor cells
(or cells are reactive only in part of
the membrane)
Tumor cell cluster with a faint or
barely perceptible membranous reactivity
irrespective of percentage of tumor
cells stained
Negative
2+ Weak-to-moderate complete basolateral
or lateral membranous reactivity
in ‡ 10% tumor cells
Tumor cell cluster with a weak-to-moderate
complete, basolateral or lateral membranous
reactivity irrespective of percentage of
tumor cells stained
Equivocal
3+ Strong complete basolateral or lateral
membranous reactivity in ‡ 10%
tumor cells
Tumor cell cluster with a strong complete,
basolateral or lateral membranous reactivity
irrespective of percentage of tumor cells stained
Positive
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patients, is evaluating safety and efficacy of modified
FOLFOX 6 regimen in combination with ramucirumab
(IMC-1121B) or icrucumab (IMC-18F1) or without investi-
gational therapy as second-line therapy in patients with
mCRC after disease progression on first-line irinotecan-based
therapy. The primary objective of the study is PFS and first
partial results are expected by the end of 2013.
6. Expert opinion
This review article aimed to highlight the effects of using
mAbs targeting specific molecules in the treatment of
gastrointestinal cancers.
At present, the mAbs adopted in gastrointestinal tumors
therapy are directed against VEGF (bevacizumab), EGFR
(cetuximab and panitumumab) or HER2 (trastuzumab).
In particular, in mCRC the addition of bevacizumab
improved clinical outcomes either in first-line chemotherapy
(in association with IFL regimen only) or in second-line treat-
ment (in association with FOLFOX4). Moreover, controversial
results are still available regarding the impact of bevacizumab
addition to chemotherapy on liver metastases.
On the other hand, evidence has been provided that the
addition of cetuximab to irinotecan-based chemotherapy in
gastrointestinal cancer improved the efficacy of treatment in
selected KRAS wild-type patients. In particular, the effective-
ness of cetuximab was shown either in monotherapy or asso-
ciated with irinotecan in patients with irinotecan-refractory
CRC. On the contrary, contrasting reports are available about
the benefits of associating cetuximab to FOLFOX regimen.
Finally, the addition of cetuximab to neoadjuvant treatment
improved the efficacy on liver metastases.
In wild type KRAS mCRC, panitumumab has shown an effi-
cacy against BSC in patients with disease progression after dif-
ferent chemotherapy treatments. Furthermore, a better efficacy
than first- or second-line FOLFOX treatment alone has been
shown by the association with panitumumab. In KRAS-
mutated patients, the association with panitumumab did
not show significant difference in comparison to irinotecan-
based treatment alone, whereas worse clinical outcomes were
evidenced in association with oxaliplatin-based treatment. At
present, panitumumab is considered to exert a less powerful
action than cetuximab, and its efficacy in patients with disease
progression on cetuximab remains still unproven.
The combination of trastuzumab with chemotherapy for
first-line treatment of HER2-positive advanced gastric or gas-
troesophageal junction cancer could represent a new standard
therapy for patients affected by inoperable/metastatic gastric
or gastroesophageal junction cancer.
As a general observation, the highest efficacy of mAbs in
gastric and CRC has been shown in combination with chemo-
therapy, although in selected mCRC patients, anti-EGFR
antibodies have proven to be efficacious in monotherapy.
Moreover, no clear results are still available about an improved
outcome induced by the addition of anti-VEGF or anti-
EGFR antibodies to chemotherapy in patients with resectable
CRC metastases. Furthermore, a univocal evidence of efficacy
in adjuvant setting was not shown.
At present, the prognosis of gastrointestinal cancers in the
metastatic phase remains critical and new studies are needed
to identify new molecules in order to offer new opportunities
to patients. Among these, edrecolomab and catumaxomab,
both directed against the EpCAM, are the most promising
agents. Early clinical data on edrecolomab indicate an antitumor
activity and could be beneficial for advanced cancer patients.
However, a lack of efficacy of edrecolomab was shown in the
adjuvant setting of colon cancer patients. Catumaxomab has
been studied for the intraperitoneal treatment of malignant asci-
tes in patients with EpCAM-positive epithelial tumors, increas-
ing the intervals between symptomatic therapeutic paracentesis.
The main mechanism of resistance for oncogene-directed
mAbs seems to be the development of ‘escape routes’, through
the activation of alternative signaling pathways bypassing the
effects of mAbs on receptors. A further mechanism of resis-
tance may be the acquisition of mutations by which the cell
becomes independent from the drug-mediated signaling block.
Contributions from basic research could help in identifying
new target molecules. Interesting results have been obtained
by aflibercept, a VEGF trap. Till now molecules directed
against VEGFR had limited development because of related
toxicity. To date some anti-VEGFR mAbs are under develop-
ment to overcome resistance of standard treatment and to
provide alternative strategies.
Even though the combination of mAbs with chemotherapy
allowed an advancement of treatment-induced survival bene-
fit, further strategies of combination with different doses
need to be developed to optimize management of particular
patient settings.
The research effort aims to find more ‘tailored’ systemic
therapy protocols, through a selection of patients on the basis
of biomarkers useful as prognostic indicators of response to
treatment. Although some tests are available in order to per-
form such a selection, further biomarkers need to be evaluated
to improve the prognostic predictability.
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